GRFS vs BCRX vs RARE vs HALO

For growth investors, BioCryst Pharmaceuticals, Inc.

(BCRX) is the stronger pick with 94. 1% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). BioCryst Pharmaceuticals, Inc. (BCRX) offers the better valuation at 7. 1x trailing P/E, making it the more compelling value choice. Analysts rate Grifols, S. A. (GRFS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, BioCryst Pharmaceuticals, Inc.

(BCRX) is the cheapest at 7. 1x versus Halozyme Therapeutics, Inc. at 25. 0x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +39. 1%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: HALO returned +559. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 166% more volatile than HALO relative to the S&P 500.

By revenue growth (latest reported year), BioCryst Pharmaceuticals, Inc.

(BCRX) is pulling ahead at 94. 1% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: BioCryst Pharmaceuticals, Inc. grew EPS 381. 4% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, BCRX leads at 47. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioCryst Pharmaceuticals, Inc.

(BCRX) is the more profitable company, earning 30. 2% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 30. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — BCRX leads at 97. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 0x forward P/E versus 9. 4x for Grifols, S. A. — 1. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BCRX: 95. 6% to $16. 86.

In this comparison, GRFS (2.

6% yield) pays a dividend. BCRX, RARE, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Both have compounded well over 10 years (HALO: +559. 7%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRFS is a small-cap deep-value stock; BCRX is a small-cap high-growth stock; RARE is a small-cap high-growth stock; HALO is a small-cap high-growth stock. GRFS pays a dividend while BCRX, RARE, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.